Lotrel, A Single Pill Combination For Treating High Blood Pressure, Reduced Cardiovascular Events By 20% In High-Risk Patients
Interim results from the ACCOMPLISH
(Avoiding Cardiovascular Events through COMbination Therapy in Patients
LIving with Systolic Hypertension) trial demonstrate that high-risk, high
blood pressure patients treated with Lotrel(R) (amlodipine besylate and
benazepril HCl) had 20% fewer cardiovascular events than those taking a
benazepril and hydrochlorothiazide (HCTZ) combination. This is the first
cardiovascular outcomes trial in a hypertensive population where all
patients were randomized to receive a single-pill combination treatment at
the onset of the trial as opposed to a step care regimen.
"These results suggest that the combination of the
angiotensin-converting enzyme inhibitor (ACEI) and calcium channel blocker
in Lotrel yielded better patient outcomes in high-risk hypertensive
patients than the ACEI and HCTZ combination," explained Kenneth Jamerson,
MD, professor of internal medicine at the University of Michigan Medical
Buy soma pills Center in Ann Arbor and lead investigator of the trial. "Further, a
strategy of starting patients in the trial on a single-pill combination
proved to be very efficient in significantly increasing blood pressure
control rates."
Lotrel is approved for the treatment of high blood pressure. It should
not be used before other medications have been tried first.
Treatment with combination therapy resulted in exceptional blood
pressure control at 30 months. Before entering the study, almost all
patients were treated with multiple high blood pressure medicines. At study
entry, only 37% of the study population had a blood pressure of Buy cialis without prescription | Buy generic propecia | Generic ultram pills no prescription
Tags: amlodipine, benazepril, blood, hydrochlorothiazide, hypertension, hypertensive, pressure